Creative BioMolecules news

To conserve cash and focus on its dentin regeneration program and its orthopedic reconstruction program, CBMI said it will reduce its staff to 156 employees from 195 by year end.

The company last week trimmed its staff to 161. CBMI said some manufacturing positions had become redundant with the transfer of its OP-1 manufacturing facilities to New Hampshire from its Hopkinton, Mass., headquarters. CBMI is under contract to provide OP-1, a precursor protein secreted by the kidney, to partner Stryker Corp., which is conducting a pivotal trial of OP-1 in orthopedic reconstruction. ...